Artriti olmayan Psoriasis Hastalarinda Kemik Mineral Yoğunluğunun Değerlendirilmesi

Öz

Çalışmamızda eklem tutulumu olmayan psoriasis hastalarında kemik mineral yoğunluğunu (KMY) değerlendirilerek sağlıklı kontrol grubu ile karşılaştırmayı ve topikal kortikosteroid ve sistemik tedavi kullanımının KMY üzerine etkisini göstermeyi amaçladık. Çalışmaya hastanemiz dermatoloji polikliniğine başvuran 40 psoriasis hastası ve 36 sağlıklı gönüllü dahil edildi. Hasta ve kontrol grubunun lomber ve femur KMY ölçüldü. Psoriazis ve sağlıklı kontrol gruplarında KMY açısından istatistiksel olarak anlamlı bir fark bulunmadı. Topikal ve sistemik tedavi alan psoriasisli hastaların L1-L4 skorları, femur KMY, L1-L4 BMD, femur Z, omurga Z ve kalsiyum değerleri karşılaştırıldığında, istatistiksel olarak anlamlı fark bulunmadı. Topikal tedavi alan grupta femur boynu T skoru, sistemik tedavi alan gruba göre anlamlı olarak daha yüksekti. Hastalık  süresi ve şiddeti arasında istatistiksel olarak anlamlı fark yoktu. L1-L4 skorları, L1-L4 BMD, omurga Z, kalsiyum değerleri, tırnak tutulumu ve tırnak tutulumu olmayan gruplar arasında anlamlı farklılık göstermedi. Ancak femur boynu, femur total ve femur Z skorları tırnak tutulumu olan grupta tırnak tutulumu olmayan gruba göre anlamlı olarak düşüktü.Bu çalışma psoriasisli hastalarında, KMY’nin sağlıklı kontrol grubundan farklı olmadığını göstermektedir.

Anahtar Kelimeler

• kemik mineral yoğunluğu,osteoporoz,artrit,sedef

Assessment of Bone Mineral Density in Psoriasis Patients without Arthritis

Öz

In this study, we aimed to investigate the bone mineral density (BMD) of psoriasis patients, compare with healthy control group, and to evaluate whether topical corticosteroids and systemic treatments affect BMD in psoriasis patients. Forty psoriasis patients admitted to dermatology outpatient clinic and 36 healthy subjects were included in the study. Lumbar and femur BMD of patient and control groups were measured. No statistically significant difference was found with regard to BMD in psoriasis and healthy control groups. When we compare the L1-L4 scores, femur BMD, L1-L4 BMD, femur Z, spine Z, and values of the psoriasis patients who receiving topical and systemic treatments, we did not found statistically significant difference. Femur neck T score was significantly higher in the group receiving topical treatment than in the group receiving systemic treatment. There were not statistically significant difference between disease duration and severity. The L1-L4 scores, L1-L4 BMD, spine Z values did not differ significantly between nail involvement and non-nail involvement groups. But the femur neck, femur total and femur Z scores were significantly lower in the group with nail involvement than group without nail involvement. This study shows that BMD of psoriasis patients is not different from healthy control group.

Anahtar Kelimeler

• psoriasis,arhritis,bone mineral density,osteoporosis

Kaynakça

1. 1. Prey S, Paul C, Bronsard V, et al. Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. J Eur Acad Dermatol Venereol 2010;24:23-30.
2. 2. Dowlatshahi EA, van der Voort EA, Arends LR, et al. Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis. Br J Dermatol 2013;169:266-82.
3. 3. Camp RDR. Psoriasis. In: Champion RH, Burton JL, Burns DA et al. (eds). Textbook of Dermatology. Malden: Blackwell Science, 1998: 1589-649.
4. 4. Ritchlin C, Haas-Smith SA, Hicks D, et al. Patterns of cytokine production in psoriatic synovium. J Rheum 1998;25:1544-52.
5. 5. Veale DJ. Newtherapies and new goals for psoriatic arthritis. Arthritis Rheum 2011;63:874-76.
6. 6. Cassell S, Kavanaugh A. Psoriatic arthritis: pathogenesis and novel immunomodulatory approaches to treatment. J Immune Based Ther Vaccines 2005;3:6-9.
7. 7. Haroon M, Fitzgerald O. Pathogenetic overview of psoriatic disease. J Rheumatol Suppl 2012;89:7-10.
8. 8. Ritchlin CT, Haas-Smith SA, Li P, et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003;111:821-31.

9. 9. Matkovic V, Colachis SC, Ilich JZ. Osteoporosis: Its prevention and treatment. In: Braddom R, Buschbcher RM, Dumitru D. (eds). Physical Medicine and Rehabilitation. Philadelphia: WB Saunders Company, 1996: 851-76.
10. 10. Kanis JA, Delmas P, Burckhardt P, et al. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 1997;7:390-406.
11. 11. Kanis JA, Melton LJ, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-41.
12. 12. Dreiher J, Weitzman D, Cohen AD. Psoriasis and osteoporosis: a sex-specific association? J Invest Dermatol. 2009;129:1643-9.
13. 13.Millard TP, Antoniades L, Evans AV, et al. Bone Mineral density of patients with chronic plaque psoriasis. Clin Exp Dermatol. 2001;26:446-8.
14. 14. DiGiovanna JJ, Sollitto RB, Abangan DL, et al. Osteoporosis is a toxic effect of long-term etretinate therapy. Arch Dermatol 1995;131:1263-7.
15. 15.McMullen EA, Irvine AD, Dolan OM, et al. The risk of osteoporosis in association with acitretin therapy. Br J Dermatol 1999;141:78.
16. 16. Buckley LM, Leib ES, Cartularo KS, et al. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 1997; 24:1489-94.
17. 17. Mazanec DJ, Grisanti JM. Drug-induced osteoporosis. Cleve Clin J Med 1989; 56: 297-303.
18. 18. Riesco M, Manzano F, Font P, et al. Osteoporosis in psoriatic arthritis: an assessment of densitometry and fragility fractures. Clin Rheumatol 2013;32:1799–804.
19. 19. Pedreira PG, Pinheiro MM, Szejnfeld VL. Bone mineral density and body composition in postmenopausal women with psoriasis and psoriatic arthritis. Arth Res Ther. 2011;13:R16.
20. 20. Van der Weijden MA, Van der Horst-Bruinsma IE, Van Denderen JC, et al. High frequency of vertebral fractures in early spondylarthropathies. Osteoporos Int 2012;23:1683-90.
21. 21. Millard TP, Antoniades L, Evans AV, et al. Bone mineral density of patients with chronic plaque psoriasis. Clin Exp Dermatol 2001;26:446-8.
22. 22. D'epiro S, Marocco C , Salvi M, et al. Psoriasis and bone mineral density: Implications for long‐term patients. J Dermatol 2014,41:783-787.
23. 23. Solak, B, Dikicier BS, Celik HD, et al. Bone Mineral Density, 25‐OH Vitamin D and Inflammation in Patients with Psoriasis. Photodermatol Photoimmunol Photomed 2016;32:153-60.
24. 24. Grazio S, Cvijetic, Vlak T, et al. "Osteoporosis in psoriatic arthritis: is there any? ".Wien Klin Wochenschr 2011;123:743-50
25. 25. Sabat R, Philipp S, Hoflich C, et al. Immunopathogenesis of psoriasis. Exp Dermatol 2007;16:779-98.
26. 26. Stolina M, Adamu S, Ominsky M, et al. RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J Bone Miner Res 2005;20: 1756-65.
27. 27. Poikolainen K, Reunala T, Karvonen J. Smoking alcohol and life events related to psoriasis among women. Br J Dermatol 1994;130:473-7.
28. 28.Eastell R. Treatment of postmenopausal osteoporosis. New Engl J Med 1998; 338: 736-46.
29. 29.De Silva BD, Savin JA. The prevention of osteoporosis in dermatology patients with on long term systemic steroids. Br J Dermatol 1999;141:85.
30. 30.Cooper C, Poll V, McLaren M, et al. Alterations in appendicular skeletal mass in patients with rheumatoid, psoriatic, and osteoarthropathy. Ann Rheum Dis 1988;47:481-4.
31. 31.Reid DM, Kennedy NS, Nicoll J, et al. Total and peripheral bone mass in patients with psoriatic arthritis and rheumatoid arthritis. Clin Rheumatol 1986;5:372-8.
32. 32.DiGiovanna JJ, Sollitto RB, Abangan DL, et al. Osteoporosis is a toxic effect of long-term etretinate therapy. Arch Dermatol 1995;131:1263-7.
33. 33. Irvine AD, Dolan OM, Bingham EA, Allen GE.The risk of osteoporosis in association with acitretin therapy. Br J Dermatol 1999;141:78. ,
34. 34.Buckley LM, Leib ES, Cartularo KS, et al. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 1997;24:1489-94.
35. 35. Nolla JM, Fiter J, Rozadilla A, et al. Bone mineral density in patients with peripheral psoriatic arthritis. Rev Rheum Engl Ed 1999;10:457-61.
36. 36. Borman P, Babaoğlu S, Gur G, et al. Bone mineral density and bone turnover in patient with psoritic artritis. Clin Rheumatol 2008;27:443-47.
37. 37. Dheda K, Cassim B, Patel N, et al. A comparison of¬ bone mineral density in Indians with psoriatic polyartritis and healthy Indian volunteers. Clin Rheumatol 2004;23:89.
38. 38. Joffe I, Epstein S. Osteoporosis associated with rheumatoid arthritis: pathogenesis and management. Semin Arthritis Rheum 1991:20:256-72.
39. 39. Preston SJ, Diamond T, Scott A, et al. Methotrexate osteopathy in rheumatic disease. Ann Rheum Dis 1993;52:582-5.
40. 40.Israel E, Banerjee TR, Fitzmaurice GM, et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001;345:941-7.
41. 41. Köse N, Kutlugün C. Psoriasis vulgarisli hastalarda kemik mineral yoğunluğu ölçümü. 2013;40:621-6.
42. 42.Osmancevic A, Landin-Wilhelmsen K, Larkö O, et al. UVB therapy increases 25(OH) vitamin D synthesis in postmenopausal women with psoriasis. Photodermatol Photoimmunol Photomed 2007;23:172-8.
43. 43. Sivri A, Çöplü L. Effect of the long-term use of inhaled cor¬ticosteroids on bone mineral density in asthmatic women. Respirology 2001;6:131-4.